Figure 4.

RNA-sequencing analyses. (A) Increase or decrease of gene expression from screening to C3D22, split by treatment arm. CD3D (T-cell gene), PDCD1 (PD-1), CD274 (PD-L1), interferon-γ signature (mean of 4 genes [CD274, LAG3, IFNG, CXCL9]), CD34 (gene expressed on tumor cells), and PNMA5 (cancer-testis antigen). The x-axis is the log₂ of the fold change between C3D22 and screening for patients with samples at both time points. (B) Interferon-γ signature at screening and at C3D22 in responders vs nonresponders to treatment with azacitidine and durvalumab (Arm A) or azacitidine monotherapy (Arm B). The plot on the left shows the screening samples and C3D22 samples separately, with lines connecting those which are from the same patient. The y-axis is the expression score. The right plot shows the fold change for those patients with both time points. The y-axis is the log₂ of the fold change between C3D22 and screening. For all plots in A and B, the line in the middle of the box is the mean, and the edges of the boxes are the 90% CIs.